EMERYVILLE, Calif., April 7, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage Biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today announced that Dmitri Debabov, Ph.D., Associate Director of Microbiology and Cell Biology, will give a presentation on the company’s lead Aganocide® compound at the Cambridge Healthtech Institute’s 5th annual “Drug Discovery Chemistry” conference in San Diego. April 27-29.
